OGN 250117 35.00P (OGN250117P35000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

OGN250117P35000

Watchlist

17.40
0.000.00%

15min DelayTrading Oct 10 10:47 ET

0.00High0.00Low

Intraday

5D
Daily

News

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
BusinesswireDec 19, 2024 07:30 ET
Goldman Sachs Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $20
Moomoo NewsDec 17, 2024 19:31 ET · Ratings
Organon Gets Expanded FDA Approval for VTAMA
Seeking AlphaDec 16, 2024 10:12 ET
Organon Says Vtama Cream Approved by FDA for Atopic Dermatitis
MT NewswiresDec 16, 2024 08:24 ET
FDA Approves Organon's Vtama (Tapinarof) For An Additional Indication Of The Topical Treatment Of Atopic Dermatitis In Adults And Pediatric Patients 2 Years Of Age And Older, Prior To Its Extended Target Action Date Of March 12, 2025
BenzingaDec 16, 2024 07:32 ET
Express News | FDA Approves Vtama® (Tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
ReutersDec 16, 2024 07:30 ET

Comments

Jaguar8

Oct 28, 2024 08:26

NEWS

$Organon & Co (OGN.US)$
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global health...

Meltyy

Oct 11, 2024 01:22

🚨 M&A Update! 🚨

Keep an eye on these recently announced & closed M&As: 👀
🟢 Recently Announced:
⇒ $Organon & Co (OGN.US)$ to acquire Dermavant
⇒ $Rafael Holdings (RFL.US)$ to acquire Cyclo Tx
⇒Crown Lab to acquire $Revance Therapeutics (RVNC.US)$
⇒ $Recursion Pharmaceuticals (RXRX.US)$ merger with Exscientia
🔴 Recently Closed:
⇒ $Johnson & Johnson (JNJ.US)$ acquired V-Wave
⇒ Pharmacosmos acquired $GTHX
What companies will be next? 🤔

whqqq

Jul 29, 2024 21:17

Cramer’s Lightning Round: Do not sell Constellation Energy

$Bank of America (BAC.US)$ : ”...You buy some right here, you buy some maybe if it breaks 40. I think this company is selling very inexpensively, and it’s a good one.”
$Illumina (ILMN.US)$ : “No. No Illumina. I like Danaher.”
$Constellation Energy (CEG.US)$ : “This is a solar play that is a very good company. It’s up a huge amount versus a lot of other stocks...I think you buy some, please hold on to it, do not sell it.”
$Meta Platforms (META.US)$ : “I thin...

https://www.youtube.com/watch?v=X4PV1Nqu1QU

From YouTube

Moomoo AI

Apr 6, 2024 07:51

Organon's low P/E ratio is due to its predicted growth being less than the broader market. Shareholders accept this as they anticipate future earnings won't bring any pleasant surprises. The share price is unlikely to rise significantly soon under these conditions.

Organon & Co.'s (NYSE:OGN) Earnings Are Not Doing Enough For Some Investors

Moomoo AI

Feb 18, 2024 17:32

Analysts show increased negativity towards the business following recent results, reflected in a minor decrease in next year's EPS estimates. Despite predicted earnings decline, Organon's valuation is not expected to be significantly affected, but growth is anticipated to lag behind the industry.

Organon & Co. Just Beat EPS By 70%: Here's What Analysts Think Will Happen Next